+

WO2008061647A8 - Use of a compound as vegf inhibitor - Google Patents

Use of a compound as vegf inhibitor

Info

Publication number
WO2008061647A8
WO2008061647A8 PCT/EP2007/009767 EP2007009767W WO2008061647A8 WO 2008061647 A8 WO2008061647 A8 WO 2008061647A8 EP 2007009767 W EP2007009767 W EP 2007009767W WO 2008061647 A8 WO2008061647 A8 WO 2008061647A8
Authority
WO
WIPO (PCT)
Prior art keywords
compound
agent
vegf inhibitor
vegf
dimethoxybenzylideneamino
Prior art date
Application number
PCT/EP2007/009767
Other languages
French (fr)
Other versions
WO2008061647A1 (en
Inventor
Torbjoern Lundstedt
Gunilla Ekstroem
Original Assignee
Acure Pharma Ab
Torbjoern Lundstedt
Gunilla Ekstroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acure Pharma Ab, Torbjoern Lundstedt, Gunilla Ekstroem filed Critical Acure Pharma Ab
Publication of WO2008061647A1 publication Critical patent/WO2008061647A1/en
Publication of WO2008061647A8 publication Critical patent/WO2008061647A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There is disclosed the use of N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine or a pharmacologically acceptable salt thereof as an agent for use in the inhibition of Vascular Endothelial Growth Factor (VEGF). Such an agent is likely to be of application in the treatment or prevention of undesired blood vessel formation during tumour growth and/or in inflammatory conditions.
PCT/EP2007/009767 2006-11-23 2007-11-12 Use of a compound as vegf inhibitor WO2008061647A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0623381.1 2006-11-23
GBGB0623381.1A GB0623381D0 (en) 2006-11-23 2006-11-23 Use of a compound as VEGF inhibitor

Publications (2)

Publication Number Publication Date
WO2008061647A1 WO2008061647A1 (en) 2008-05-29
WO2008061647A8 true WO2008061647A8 (en) 2008-11-27

Family

ID=37636386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/009767 WO2008061647A1 (en) 2006-11-23 2007-11-12 Use of a compound as vegf inhibitor

Country Status (2)

Country Link
GB (1) GB0623381D0 (en)
WO (1) WO2008061647A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
CN102573993A (en) * 2009-07-31 2012-07-11 Anamar股份公司 Compounds for treatment of inflammation
AU2015282900B2 (en) 2014-07-02 2020-06-18 Inflectis Bioscience Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
ES2749657T3 (en) 2014-07-02 2020-03-23 Inflectis Bioscience Derivatives of O-alkyl-benzylidenguanidine and its therapeutic use for the treatment of disorders associated with an accumulation of misfolded proteins
JP2021529729A (en) 2018-05-09 2021-11-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Use of guanabenz or its derivatives for treating type I IFN-dependent pathologies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599984A (en) * 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
SE9604348D0 (en) * 1996-11-26 1996-11-26 Wapharm Ab Use of hydroxyguanidines
GB0019357D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines

Also Published As

Publication number Publication date
GB0623381D0 (en) 2007-01-03
WO2008061647A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2010021680A3 (en) Inhibitors of beta-secretase
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
WO2009005269A3 (en) Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2011052923A3 (en) Novel 1,6-disubstituted indole compounds as protein kinase inhibitors
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
EP2607348A3 (en) Plasminogen Activator Inhibitor-1 Inhibitor
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
WO2006011631A3 (en) Thiazole derivatives having vap-1 inhibitory activity
WO2007109251A3 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
TW200420549A (en) Thiazole derivatives
WO2009086426A3 (en) Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
WO2008061647A8 (en) Use of a compound as vegf inhibitor
BRPI1011804A2 (en) pharmaceutical composition with improved solubility
WO2008027013A3 (en) Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
IL192600A0 (en) Method of treating or preventing tissue damage caused by increased blood flow
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
EA200900862A1 (en) DERIVATIVES OF PROSTACYCLINE
WO2006083710A3 (en) Use of 5-ht4 agonist for treating delayed gastric emptying which may be induced by a proton pump inhibitor
WO2007130419A3 (en) Histone deacetylase inhibitors for the treatment of neurodegeneration
NZ624708A (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
ATE551052T1 (en) USE OF RENIN INHIBITORS TO PREVENT OR TREAT DIASTOLIC DYSFUNCTION OR DIASTOLIC HEART FAILURE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07819756

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07819756

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载